Navigation Links
Volcano Corporation Schedules Second Quarter Conference Call, Webcast
Date:7/29/2008

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the second quarter and first six months of fiscal 2008 on Tuesday, August 5.

The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time), Tuesday, August 5, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer.

The teleconference can be accessed by calling (719) 325-4886, passcode 4988988. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available through the company's website at http://www.volcanocorp.com.

A replay of the conference call will be available through Monday, August 11, at (719) 457-0820, passcode 4988988, and via the company's website.

About Volcano Corporation

Volcano Corporation (NASDAQ: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH(TM) tissue characterization and ChromaFlo(R). Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra high-resolution Optical Coherent Tomography (OCT) systems and catheters. Currently, more than 3,300 Volcano IVUS and FM systems are installed worldwide with approximately half of its revenues coming from outside the United States. For more information, visit the company's website at http://www.volcanocorp.com.


'/>"/>
SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Volcano Announces Acquisition of Novelis, Inc.
2. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System
3. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
6. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
7. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
8. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
9. Volcano Announces Closing of CardioSpectra Acquisition
10. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
11. Volcano Corporation Announces Pricing of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):